Amgen v Sanofi-Aventis Deutschland (CFI, 24 August 2023)
| Date | 24 August 2023 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Central Division - Section |
| Type of action | Preliminary objection |
| Case number(s) | UPC_CFI_1/2023 |
| Registry reference | ORD_560432/2023 · UPC_CFI_1/2023 |
| Parties | Amgen, Inc. v. Sanofi-Aventis Deutschland GmbH |
Official decision (PDF) · UPC registry entry
Case timeline
- 29 June 2023 : Sanofi-Aventis Deutschland v Amgen (CFI, 29 June 2023) ORD_536514/2023 · UPC_CFI_1/2023
- 20 September 2023 : Sanofi-Aventis Deutschland v Amgen (CFI, 20 September 2023) ORD_550152/2023 · UPC_CFI_1/2023
- 24 January 2024 : Sanofi-Aventis Deutschland v Amgen (CFI, 24 January 2024) ORD_2233/2024 · UPC_CFI_1/2023
- 24 February 2024 : Sanofi v Amgen (CFI, 24 February 2024) ACT_459505/2023andCC_586764/2023 · ORD_10396/2024 · ORD_10398/2024 · UPC_CFI_1/2023 · UPC_CFI_14/2023
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 24 August 2023 (UPC_CFI_1/2023, ACT_459505/2023), the judge-rapporteur of the Munich section of the Central Division rejected Amgen’s preliminary objection to Sanofi’s revocation action against EP 3 666 797. On 1 June 2023, with the CMS out of service, Sanofi had lodged its Statement for revocation in hard copy at the Luxembourg Registry at 11.26, and Amgen its infringement action at the Munich Local Division sub-registry at 11.45. The order, which grants leave to appeal of the Court’s own motion, settles to the minute the priority required by Art. 33(4) UPCA.
Question
Does the Central Division remain competent where an infringement action between the same parties on the same patent is brought before a local division on the same day, a few minutes after the revocation action?
Decision
« Bringing an action » means the objective act of lodging the statement, the requirements of Rule 13 RoP not being a precondition, since Art. 33(4) UPCA lays down no further requirement (paragraphs 4.22 and 4.23), any arbitrary assignment after an action is brought must be ruled out (paragraph 4.19). Priority is determined by the exact date and time of lodging (paragraph 4.26). Rule 4.2 RoP offers a choice between the Registry, at the seat of the Court of Appeal in Luxembourg, and a sub-registry, Amgen’s narrower reading being rejected (paragraphs 4.39 to 4.43), the Registry Rules cannot override the Rules of Procedure (paragraphs 4.49 to 4.51). The outcome is fair, as a party should not be disadvantaged merely by its geographical location (paragraph 4.52). As no infringement action was pending at 11.26, the Central Division is competent (paragraph 4.53). The costs request was rejected (paragraph 4.55).
Key points for practice
- Practical point: in a race between revocation and infringement, the exact time of lodging is decisive, the Luxembourg Registry is a valid place of filing, including when the CMS is down.
Provisions applied
- Agreement on a Unified Patent Court
- Arts. 10, 32(1), 33(2) to (4), 73(2)(b)(ii) and 83(3), Statute, Arts. 23, 24 and 25
- Rules of Procedure
- Rules 4.1, 4.2, 13, 16, 17, 19.1(b), 20.2, 21.1, 49, 220.2 and 224.1(b)
- Regulation 1215/2012
- Arts. 24(4), 31, 71a and 71b
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Local and central divisions (UPC).
Dhenne Avocats blog: The Transitional Period and the UPC: Coordinating Two Judicial Orders.
Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, Valeo v. Bosch and the Redistribution of Cases Within the UPC (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- defendantSanofi-Aventis Deutschland GmbH28 decisions in the corpusFollow this party
- claimantAmgen, Inc.24 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
- 29 June 2023 Sanofi-Aventis Deutschland v Amgen (CFI, 29 June 2023) Revocation Action · UPC_CFI_1/2023
Les documents déposés par les sociétés Sanofi sont admis comme pièces de la demande en nullité, réputée signifiée à Amgen le 29 juin 2023.
- 24 August 2023 Amgen v Sanofi-Aventis Deutschland (CFI, 24 August 2023) Preliminary objection · UPC_CFI_1/2023
- 20 September 2023 Sanofi-Aventis Deutschland v Amgen (CFI, 20 September 2023) Revocation Action · UPC_CFI_1/2023
Le juge rapporteur rejette la demande d'accès aux écritures et pièces d'un mandataire souhaitant se forger une opinion sur la validité du brevet, faute de motif concret et vérifiable, et autorise l'appel.
- 24 January 2024 Sanofi-Aventis Deutschland v Amgen (CFI, 24 January 2024) Revocation Action · UPC_CFI_1/2023
Le juge rapporteur admet la lettre des demanderesses et ses déclarations d'experts répondant à des points nouveaux de la duplique, et rejette les demandes d'Amgen tendant à la clôture immédiate ou à une réplique supplémentaire.
- 24 February 2024 Sanofi v Amgen (CFI, 24 February 2024) Revocation Action · UPC_CFI_1/2023
L'action en nullité de Sanofi et la demande reconventionnelle en nullité de Regeneron contre le brevet d'Amgen sont instruites conjointement en vue d'une audience le 4 juin 2024, la valeur de chaque action étant fixée à 100 millions d'euros.
What the record states
- Nature of the act
- Preliminary objection
- Outcome (Dhenne Avocats summary)
- L'action en nullité déposée au greffe de Luxembourg à 11 h 26 précède l'action en contrefaçon déposée à 11 h 45, la division centrale est compétente et l'exception préliminaire est rejetée.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 666 797mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Sanofi v Amgen (CFI, 24 February 2024) cited in this record
- Sanofi-Aventis Deutschland v Amgen (CFI, 24 January 2024) cited in this record
- Sanofi-Aventis Deutschland v Amgen (CFI, 20 September 2023) cited in this record
- Sanofi-Aventis Deutschland v Amgen (CFI, 29 June 2023) cited in this record
- iCAT v DENTSPLY SIRONA (CFI, 26 August 2026) cites this decision
- Pfizer v GlaxoSmithKline Biologicals (CFI, 3 December 2024) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 666 797Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) recorded proprietor: Amgen Inc | Mentioned in the analysis (role not qualified) Also mentioned in 21 other decision(s): Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) · Sanofi-Aventis Deutschland v Amgen (CFI, 16 July 2024) · Regeneron Pharmaceuticals v Amgen (CFI, 16 July 2024) · SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 25 March 2026) · SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) · Dehns v Regeneron Pharmaceuticals (CFI, 22 October 2024) · Sanofi-Aventis Deutschland v Amgen (CFI, ORD_47230/2024, 22 October 20 · Sanofi-Aventis Deutschland v Amgen (CFI, ORD_47238/2024, 22 October 20 | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.